GondolaBio is a clinical-stage biopharmaceutical company dedicated to developing next-generation therapeutics for genetic diseases. Originally part of BridgeBioX, GondolaBio became an independent entity in 2024 after securing $300M in private financing. The company is located on the Stanford Life Sciences campus and emphasizes collaboration between top scientists and senior leadership to drive innovation in multiple therapeutic areas, including neurology, pulmonology, cardiology, nephrology, and endocrinology. GondolaBio aims to address significant unmet medical needs through cutting-edge biological research and a commitment to scientific excellence.